Combination treatment before surgery for locally advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new combination treatment for stomach cancer that has not spread. You will receive propranolol (a beta-blocker), chemotherapy (SOX), and immunotherapy (toripalimab) before surgery to see if it helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stomach or gastroesophageal junction cancer that is locally advanced (has not spread to distant organs) and can be removed with surgery.
- You are in good general health, with a performance status of 0 or 1 (able to carry out daily activities).
- Your heart function is normal, including a resting heart rate of at least 60 beats per minute and no significant heart problems.
- You have not had prior chemotherapy, immunotherapy, or radiation for this cancer.
- You are willing to undergo surgery as part of the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment plan after surgery for stomach cancer that shows certain markers, to reduce the chance of the cancer coming back. It includes drugs that help your immune system fight cancer.
This study tests a combination of an immunotherapy drug (tislelizumab) with two chemotherapy drugs (called the SOX regimen) given before surgery for locally advanced stomach cancer. The goal is to see if this treatment can shrink the tumor and make it easier to remove completely during surgery.
This trial tests a combination of four drugs given before surgery to shrink stomach cancer and improve the chances of successful removal. It is for people with locally advanced stomach or gastroesophageal junction cancer that has not been treated yet.
This trial tests a combination of radiation, chemotherapy (SOX), and two targeted drugs (apatinib and camrelizumab) before and after surgery for stomach or gastroesophageal junction cancer. It aims to see if this approach is safe and effective.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a combination of chemotherapy drugs and an immunotherapy drug given before surgery for stomach cancer in younger patients. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.